SpyGlass Pharma reports positive four-year first-in-human trial data
The company announced positive four-year data from its first-in-human trial of the BIM-IOL system.
Story updates
12:04:48 PM UTC
SquawkNews
SpyGlass Pharma reported positive 4-year interim results from its first-in-human trial of the BIM-IOL System, showing sustained IOP reduction with a clear safety profile in evaluable patients (N=21). The device is designed to deliver bimatoprost for up to 7 years.Material DetailsContext by AI Analy…